Topiramate Tablet, Film Coated
Product Images NDC 68462-109

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68462-109). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1

The text represents a graph showing the cumulative rates for time to the first seizure for two different doses of topiramate (50mg/day and 400mg/day) over a period of 300 days. The graph shows the percentage of patients who have not experienced a seizure at a given time point.*

FDA Label Image

Figure2

The text describes a table showing the change in the average monthly migraine period rate from baseline to the double-blind phase for different dosages of Topiramate and Placebo. The table shows the sample size for each group and specifies the study number. The text also includes asterisks indicating statistical significance levels.*

FDA Label Image

Lbl100mg60

FDA Label Image

Lbl200mg60

FDA Label Image

Lbl25mg60

FDA Label Image

Lbl50mg60

FDA Label Image

Logo

FDA Label Image

Structure

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.